No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Tibet Cheezheng Tibetan Medicine (002287.SZ): plans to invest 90 million yuan to -0.16 billion yuan to repurchase shares.
On March 2, Gelonghui reported that Tibet Cheezheng Tibetan Medicine (002287.SZ) announced that the company plans to use its own funds to repurchase A-shares through centralized bidding, and the repurchased shares will be used for Stock-based Incentive or employee stock ownership plans. The total amount of the repurchase will not be less than 90 million yuan (inclusive) and not exceed 160 million yuan (inclusive), with the repurchase price not exceeding 31.65 yuan/share (inclusive). If calculated based on the upper and lower limits of the total repurchase amount and the upper limit of the repurchase price, the estimated number of repurchased shares is approximately 2.8436 million shares to 5.0553 million shares, accounting for about 0% of the company's total share capital.
Qizheng Tibetan Medicine: 2024 Annual Performance Report
Tibet Cheezheng Tibetan Medicine (002287.SZ) performance report: In 2024, the net income attributable to the parent company was 0.575 billion yuan, a year-on-year decrease of 0.98%.
On February 27, Gelonghui reported that Tibet Cheezheng Tibetan Medicine (002287.SZ) released its performance bulletin for the year 2024, achieving a total operating revenue of 2.338 billion yuan, a year-on-year increase of 14.31%; the net income attributable to the shareholders of the listed company was 0.575 billion yuan, a year-on-year decrease of 0.98%; the net income attributable to the shareholders of the listed company, deducting non-recurring gains and losses, was 0.423 billion yuan, a year-on-year increase of 14.44%; the basic EPS was 1.0855 yuan.
Tibet Cheezheng Tibetan Medicine (002287.SZ) disclosed a special dividend plan proposing a distribution of 2.2 yuan for every 10 shares.
Tibet Cheezheng Tibetan Medicine (002287.SZ) disclosed a special dividend plan, and the company intends to distribute Cash / Money Market of 1... for every 10 shares to all shareholders.
Tibet Cheezheng Tibetan Medicine (002287.SZ): It has advantageous products suitable for the investment market in various treatment areas, including the respiratory and digestive systems.
On November 15, Gelonghui reported that Tibet Cheezheng Tibetan Medicine (002287.SZ) stated during a specific entity research on November 14, 2024, that the company holds 141 pharmaceutical approval numbers, with products covering multiple Tibetan medicine specialty treatment areas such as orthopedics, neurology, dermatology, gynecology, pediatrics, respiratory, digestive, and cardiovascular fields. The招商 can explore and activate more quality products from the company, injecting new vitality into these products through precise market development strategies. The company has developed detailed招商 plans tailored to the different characteristics of various products. The company has suitable treatments in multiple fields including the respiratory and digestive systems.